The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic
Amgen’s effort to develop a potential obesity treatment began with genetic research at the University of Iceland Science Park in Reykjavík. The work forms part of the company’s push to compete in the high-stakes market for drugs associated with the success of Ozempic.
Amgen obesity drug drug development genetics University of Iceland Science Park